hi subpopulation of conventional granulocyte-monocyte progenitors (cGMPs) in umbilical cord blood and in bone marrow. Human cMoPs gave rise to monocyte subsets without showing any potential for differentiating into myeloid or lymphoid cells. Within the cGMP population, we also identified revised GMPs that completely lacked DC and lymphoid potential. Collectively, our findings expand and revise the current understanding of human myeloid cell differentiation pathways.
In Brief
Monocytes and monocyte-derived macrophages cause a variety of inflammatory disorders. Kawamura and colleagues identified human cMoPs, a monocyte-restricted progenitor, in umbilical-cord blood and bone marrow, increasing our understanding of human monocyte differentiation and insight for therapies targeting cMoPs and monocytes.
INTRODUCTION
Mononuclear phagocytes (MPs), which include monocytes, macrophages, and dendritic cells (DCs), have central roles in tissue homeostasis and the immune response (van Furth and Cohn, 1968; Ginhoux and Jung, 2014; Guilliams et al., 2014a) . Although the majority of healthy tissue-resident macrophages are derived from embryonic precursors, those in the intestine, heart, lung, mammary gland, dermis, and bone are derived from monocytes (Ginhoux and Jung, 2014; Guilliams et al., 2014a; Ginhoux et al., 2010; Schulz et al., 2012; Yona et al., 2013; Hashimoto et al., 2013; Gomez Perdiguero et al., 2015; Hoeffel et al., 2015) . In addition, inflammation can prompt tissue-infiltrating monocytes to differentiate into monocyte-derived macrophages and DCs, which are associated with both homeostatic host-defense reactions and inflammatory diseases (Auffray et al., 2009; Davies et al., 2013) . In mice, monocytes are divided into classical Ly6c hi -and non-classical Ly6c lo -expressing subsets (Ginhoux and Jung, 2014; Geissmann et al., 2003; Ziegler-Heitbrock et al., 2010; Auffray et al., 2007) . Ly6c lo monocytes are present only in the blood, whereas Ly6c hi monocytes are found in both the blood and other tissues, where they differentiate into macrophages and DCs (Ginhoux and Jung, 2014; Yona et al., 2013; Varol et al., 2007) . In this context, most Ly6c lo monocytes are thought to be derived from Ly6c hi monocytes (Ginhoux and Jung, 2014; Yona et al., 2013; Varol et al., 2007 (Ingersoll et al., 2010) .
Monocytes arise from hematopoietic stem cells (HSCs) via sequential intermediate progenitors in the bone marrow (BM).
A common monocyte progenitor (cMoP) that is restricted to the monocyte lineage has been identified in mice (Hettinger et al., 2013) . These cMoPs are thought to be derived from macrophage-DC progenitors (MDPs) (Hettinger et al., 2013; Fogg et al., 2006) . In humans, myeloid progenitors such as common myeloid progenitors (CMPs), megakaryocyte and erythroid progenitors (MEPs), and granulocyte and monocyte progenitors (GMPs) are identified by their relative expressions of interleukin-3 (IL-3) receptor (CD123), Flt3 (CD135), and CD45RA (Manz et al., 2002; Doulatov et al., 2010) . Another progenitor, human MDP, has been recently discovered in a GMP fraction . As with mouse MDPs, human MDPs give rise to monocytes, macrophages, and DCs, although their lymphoid potential remains to be assessed. Given the presence of human GMPs and MDPs, one can imagine the downstream presence of human cMoPs that give rise to monocytes and macrophages but not to any other hematopoietic lineages.
To identify human cMoPs, we focused on the expression of FcgRI (CD64) and C-type lectin CLEC12A, which are highly expressed on monocytes and macrophages and weakly on DCs (Guilliams et al., 2014b; Olweus et al., 1995; Neumann et al., 2014; Lahoud et al., 2009 ). We used these markers to divide conventional GMPs into four subpopulations. Among them, we found human cMoPs as CLEC12A hi CD64 hi cells. The presence of MDPs and cMoPs within the conventional GMP population implies that conventional GMPs are actually a mixed population of genuine GMPs and other progenitors, and this finding led us to redefine human GMPs as a subset of CLEC12A hi CD64 int cells within the conventionally defined GMP population. This subset of revised GMPs gave rise sequentially to cMoPs, pre-monocytes, and monocytes, and this process probably did not involve MDPs. The identification of human cMoPs and of revised GMPs provides insight into human myeloid cell differentiation pathways.
RESULTS

Conventional Human GMPs Are Divided into Four Subpopulations
Conventional GMPs (hereafter cGMPs), defined as Lin
+ cells (Manz et al., 2002; Doulatov et al., 2010) , dominantly contain granulocyte-monocyte progenitors, but also include some cells that can differentiate into T cells (Doulatov et al., 2010) . After screening cytokine receptors, chemokine receptors, and others, we selected C-type lectin CLEC12A and FcgRI (CD64), both of which are highly expressed on mouse and human monocytes, as markers to investigate cGMP subsets (Figure 1 ; Guilliams et al., 2014b; Olweus et al., 1995; Neumann et al., 2014; Lahoud et al., 2009) . In this context, common DC progenitors (CDPs) restricted to DC differentiation have been recently identified in cGMPs in the human umbilicalcord blood and BM . The CDPs were CD123 hi and thus not included in the cGMPs defined in our study ( Figure 1A ). We used multi-color flow cytometry to subdivide cGMPs from human umbilical cord blood into four fractions based on CLEC12A and CD64 expression: CLEC12A hi CD64 hi (R2), CLEC12A hi CD64 int (R3), CD64 À CLEC12A + (R4), and CD64 À CLEC12A À (R5) ( Figure 1A ). We also defined a CLEC12A hi CD64 hi fraction in Lin
The surface phenotypes of R1 and R2 were very similar except that R2 cells expressed CD34 and R1 cells did not. We detected these five fractions (R1-R5) in human BM. In contrast, we hardly detected them in human peripheral blood (PB) (Figure 1B) . Unless otherwise specified, the cGMPs from umbilical-cord blood were analyzed hereafter.
To assess the myeloid-erythroid differentiation potential of the R1-R5 fractions, we assayed the colony-forming units (CFUs) ex vivo ( Figure 1C À common myeloid progenitors (CMPs) ( Figure 1A ; Doulatov et al., 2010; Manz et al., 2002) . The R3 and R4 fractions gave rise to macrophage (M), granulocyte-macrophage (GM), and granulocyte (G) colonies, although more macrophage CFUs arose from the R4 than the R3 fraction. Interestingly, the R2 and R5 fractions gave rise only to M colonies, and the R1 fraction gave rise to few myeloid CFUs. As expected from previous cGMP studies (Manz et al., 2002; Doulatov et al., 2010) , none of the fractions produced E or GEMM CFUs ( Figure 1C ). Of note, the myeloid-development potential of the R1-R3 fractions correlated well with their CD34 and CD38 expression amounts, cell size ( Figure S1A ), and morphology ( Figure 1D ). We gated the R1-R3 fractions back into CD34 and CD38 or lineage (Lin) and CD34 profile; R3 cells were CD34   +   CD38  + , R2   cells showed downregulated CD34 expression (CD34   int   CD38   +   ) , and R1 lost CD34 almost entirely (CD34 À CD38 + ) ( Figure S1A ).
The cytoplasmic volume gradually increased from R3 to R1, which was positively and inversely correlated with their CD64 expression amounts and myeloid CFU activity, respectively (Figures 1B, 1C, and S1A) . With regard to cell morphology, the R2-R5 fractions had typical progenitor morphology, with round, enlarged nuclei and a comparatively small volume of cytoplasm ( Figure 1D ). Collectively, these results showed that cGMPs can be fractionated into four unique subpopulations with distinct myeloid cell differentiation potentials.
Human cMoPs and Revised GMPs Are Identified in Conventional Human GMPs
As the R1-R5 fractions had different myeloid-cell differentiation potentials, we set up an in vitro culture system to detect granulocytes, monocytes, and DC subsets using a previously described gating strategy ( Figure S1B ; Haniffa et al., 2012; Abeles et al., 2012) . Each fraction sorted from umbilical-cord blood was cultured and chased for 1 day (R1), 3 days (R2), 6 days (R3), or 8 days (R4, R5) in the presence of Fms-like tyrosine kinase receptor-3 ligand (Flt3L), thrombopoietin (TPO), and stem-cell factor (SCF) (hereafter, FTS). We chose these time points for each fraction's progeny production based on the results of time-course experiments ( Figures 2D, 2E , and S1C). As expected, the more upstream the progenitor, the longer the differentiation time was. Consistent with the in vitro colony-forming assay ( Figure 1C ), the R3 and R4 fractions were able to differentiate into granulocytes, while R1, R2, and R5 were not (Figures 2A  and Table S1 ). Importantly, the R1-R3 fractions gave rise to monocytes but did not produce any DC subsets, including pDCs, CD141 hi cDCs, or CD1c + cDCs (Figures 2A and Table   S1 ). Consistent with the monocytes in human blood, the most abundant monocyte subset derived from R2 and R3 was the classical CD14 + CD16 À monocytes on days 3 and 6, respec- Figure S1D ). The majority of these DCs also expressed CD16 ( Figure S1E ). In this context, we noticed that the peak R1 monocyte production, on day 2, was earlier than that of R2 ( Figures 2E and S1C) ; this finding implies that both the R1 and R2 subsets are progenitors committed to a monocyte differentiation and that R1 is a downstream progenitor of R2. On the other hand, the R4 and R5 fractions, both of which were CD64 À ( Figure 1A) , gave rise to all monocyte and DC subsets (Figures 2A and Table S1 ). The CD141 hi cDCs derived from the R4 and R5 fractions expressed CLEC9A ( Figure S1F ). Human DC subsets can be identified by cell-surface markers as follows: CD141
hi DCs express the combination of CLEC9A, CADM1, and CD26, and CD1c + DCs express CD172a (Guilliams et al., 2016) . Thus, we cultured R4 and R5 under the FTS condition and with MS5 stromal cells, Flt3L, SCF, and GM-CSF (hereafter, the MS5+FSG condition) and examined the DC subsets derived from R4 and R5 by staining for these cell-surface markers. For comparison, we evaluated the DCs in BM (Figures S2A and S2B (C) The myeloid colony-forming activity of each umbilical cord blood subpopulation. Each sorted progenitor (1 3 10 2 ) was cultured in methylcellulose medium containing the appropriate cytokine cocktail (see STAR Methods), and colonies were counted after 10 days. Each bar represents the mean number of colonies per plated cells (1 3 10 2 ) and error bars represent SD. Abbreviations are as follows: M, macrophage; GM, granulocyte-macrophage; G, granulocyte; E, erythrocyte; GEMM, granulocyte-erythrocyte-macrophage-megakaryocyte. (D) Diff-Quick staining of each umbilical cord blood progenitor. Original magnification 3 100; scale bar, 10 mm. Data are representative of (A) 4 (BM) and 3 (PB), (C and D) 3, and (A) at least 20 independent experiments. Please also see Figure S1 .
(legend on next page) condition ( Figure S2C ). These results suggested that the MS5+FSG condition is more suitable for evaluating the CD141 hi DC and CD1c + DC differentiation potential, whereas the FTS condition is better for examining monocyte and pDC differentiation. Notably, CD141 hi DCs expressed CLEC9A and CD26, and CD1c + DCs expressed CD172a under both culture conditions ( Figure S2D ). On the other hand, 30%-50% of the R4-derived and up to 15% of the R5-derived CD141 hi DCs expressed CADM1 ( Figure S2E ). The CD26 expression was not restricted to CD141
hi DCs, but was also expressed by CD1c + DCs particularly when R5 was cultured under the MS5+FSG condition. The proportion of CADM1 + CD141 hi DCs under the MS5+FSG condition was slightly higher than under the FTS condition (Figures 2A and S2C ).
We also examined the expression of transcription factors that are known to be essential for the development of DC subsets, i.e., IRF8 (CD141 hi DCs), IRF4 (CD1c + DCs), and TCF4 (pDCs), in the DCs derived from R4 and R5 ( Figure S2F ). As expected, the CD141 hi DCs expressed high amounts of IRF8 and CD1c + DCs expressed high amounts of IRF4. The pDCs expressed high amounts of not only TCF4 but also IRF8 and IRF4, consistent with a recent report (Guilliams et al., 2016) . Monocytederived CD1c + DCs express CD14, but monocyte-independent CD1c + DCs do not (Guilliams et al., 2016) . We found that the R4-and R5-derived CD1c + DCs did not express CD14 (see our definition in Figure S1B ), indicating that they were not monocyte-derived DCs. As the R1-R3 fractions showed little if any potential to differentiate into DCs, these results suggested that the R4 and R5 fractions are the primary source of DCs in cGMPs. We next examined the lymphoid differentiation potential of the R1-R5 fractions. To evaluate the T cell differentiation potential, we cultured ten cells of each fraction in the presence of Flt3L and IL-7 on Tst4 stromal cells expressing delta-like ligand 4 (Dll4), an essential Notch ligand for T cell development (Ikawa et al., 2010) . We included MLPs for comparison ( Figure 2B ). Remarkably, the R1-R3 fractions had no potential to differentiate into T cells, while the R4 and R5 fractions produced numbers of T cells. We further evaluated the B-NK potential by culturing ten cells of each fraction in the presence of SCF, TPO, IL-2, and IL-7 on Tst4 stromal cells; for comparison, we included B-NK progenitor cells, defined as Lin The lymphoid differentiation potential of the R1-R5 subsets tended to decrease with increased CLEC12A expression and was completely lost by acquiring additional CD64 (Figures 2B, 2C, S2G, and S2H). The R4 and R5 lymphoid-differentiation potential may explain the remaining T cell potential in cGMPs (Doulatov et al., 2010) .
To assess the phenotype of R5 more precisely, we set up a new culture system based on a previous report (Doulatov et al., 2010) in which both the lymphoid and myeloid potentials can be evaluated at a single-cell level. R5 generated seven types of colonies: B alone, NK alone, CD33 + myeloid (hereafter My) alone, B+NK, B+My, NK+My, and B+NK+My (Figures S2I and S2J) . These data suggested that, according to the current definition, R5 is lymphoid-primed multipotent progenitor (LMPP)-like progenitors, although R5 lacks granulocyte potential (Naik et al., 2013; Adolfsson et al., 2005) . We further characterized the R1-R5 fractions based on their expression of other growth factor receptors, such as CD110 (TPO receptor), CD115 (M-CSF receptor), CD116 (GM-CSF receptor), CD117 (SCF receptor), and CD123 (IL3 receptor a) (Figure S3A) , and of myeloid lineage markers, including HLA-DR, CD66b, BDCA-2, CD141, CD11c, and CD1c ( Figure S3B ). The expression pattern of cytokine receptors in the R1 fraction overlapped with those recently reported for pre-monocytes ; both expressed CD115, CD116, and CD117 at detectable amounts. In contrast, the expression patterns observed in the R2 and R3 fractions have never been reported. None of the myeloid lineage markers was expressed on R1-R5 fractions.
Based on these phenotypical and developmental assays, we concluded that R1 was a pre-monocyte fraction identical to the pre-monocytes that were recently defined , R2 is a cMoP, and R3 is the revised GMP population (hereafter rGMPs) ( Table 1 ). As seen with the human cMoPs and rGMPs, CLEC12A and CD64 were expressed on mouse cMoPs and GMPs ( Figures S3C and S3D ). In addition, CD135
À GMPs did not contain cMoPs ( Figure S3E ), indicating that human cMoPs express CD135, in contrast to mouse cMoPs. We also assessed whether the cMoP-derived monocytes were functional and found that (1) cMoP-derived monocytes had a phagocytotic capacity equal to that of peripheral blood monocytes ( Figure S4A ), (2) they were poor allostimulators compared to CD141
hi DCs and CD1c + DCs (Figures S4B and S4C), and (3) they effectively secreted IL-6, TNF-a, and IL-1b in response to LPS+IFN-g stimulation ( Figure S4D ).
Since human MDPs were recently identified in the cGMPs , we compared the phenotypes of human MDPs and for 1 day (R1), 3 days (R2), 6 days (R3), or 8 days (R4, R5), and the granulocytes, monocytes, and DC subsets were analyzed (see also Table S1 ). cMoPs. The MDPs did not overlap with cMoPs and were located in R3 (rGMPs) and R4 ( Figure S4E ), where they accounted for only 11.3% ± 4.56% and 8.56% ± 2.81% of the cells, respectively. Thus, R3 and R4 contained minor CD115 + populations, which were MDPs. In addition, human MDPs do not express CD116 , whereas the human cMoPs clearly did ( Figure S3A ), demonstrating that cMoPs are a distinct progenitor from MDPs. Finally, the sorted MDPs partially differentiated into cMoPs during a 24 hr culture ( Figure S4F ).
Human cMoPs and rGMPs Show Proliferative Capacity
We further evaluated the characteristics of single cMoP and rGMP cells. The cMoPs and GMPs were sorted and cultured in methylcellulose medium containing the appropriate cytokine cocktail (see STAR Methods) for 4.5 and 5.5 days, respectively, and single colonies were picked up for flow cytometry analysis. Notably, 100% of the cMoP-derived single colonies consisted exclusively of monocytes ( Figures 3A and 3C ). Among the rGMP-derived single colonies, some contained only monocytes (33.2% ± 3.5%) (mean ± SD), while others contained both monocytes and granulocytes (21.7% ± 2.8%), granulocytes alone (37.6% ± 1.9%), or undifferentiated cells (6.6% ± 2.3%) ( Figures  3B and 3C ). The frequency of bipotent progenitors was higher than that of human MDPs (12.5%) and comparable to mouse CDPs (18.0%) Onai et al., 2013) . Under the same culture conditions, 1 out of 6.85 cMoPs and 1 out of 1.04 rGMPs formed colonies, as estimated by limiting dilution analysis ( Figures 3D and 3E) . The precursor frequency of human cMoPs was comparable to that reported for human preDCs (1/ 7.84), mouse CDPs (1/7.1-8.6), and mouse cMoPs (1/3.9-9.2) (Hettinger et al., 2013; Breton et al., 2015; Onai et al., 2013) . These results formally demonstrated that the human cMoP was a unipotent progenitor, as reported for the mouse cMoP (Hettinger et al., 2013) , and that rGMPs contain some bipotent progenitors that can produce monocytes and granulocytes at the single-cell level.
To assess the heterogeneity of the cMoPs, we performed single-cell in vitro cultures ( Figures S4G and S4H ). cMoPs were cultured under clonogenic conditions, and approximately 20% of the plated cMoPs generated monocytes. In three independent experiments, a total of 61 and 50 clones were picked up at 4.5 and 5.5 days of culture, respectively, stained for CD14 and CD16, and analyzed by flow cytometry. All of the clones contained both CD14SP and DP monocytes, and none consisted of CD14SP or DP cells alone. In addition, the ratio of CD14SP to DP was substantially decreased with time (from 4.5 to 5.5 days) ( Figures S4G and S4H ). These results collectively suggested that the cMoPs are homogeneous bipotent progenitors that produce both CD14SP and DP cells and that CD14SP monocytes further differentiate into DP cells with time. Supporting this conclusion, the cMoP-derived sorted CD14SP monocytes partially gave rise to DP monocytes, whereas the cMoP-derived sorted DP monocytes remained DPs and never differentiated into CD14SP monocytes ( Figure S4I ).
As progenitors show division-coupled differentiation, we estimated the proliferative capacities of monocytes, pre-monocytes, cMoPs, and rGMPs by CFSE-dilution assays. We labeled these populations with CFSE, and 1 3 10 3 cells of each fraction were cultured in methylcellulose medium containing the appropriate cytokine cocktail for 7 days. Neither monocytes nor premonocytes showed cell division, indicated by CFSE dilution, whereas cMoPs and rGMPs exhibited substantial proliferation ( Figure 3F ). Consistent with these observations, no cells were recovered 7 days after 10 3 of the pre-monocytes were cultured, while 31,000 ± 3,875 cells were derived from 10 3 cMoPs under the same culture conditions ( Figure 3G ). Furthermore, we performed cell-cycle analysis using DAPI staining ( Figures 3H  and 3I ). The percentage of cMoPs in the mitotic phase was comparable to that of CMPs and rGMPs. Collectively, these findings showed a clear difference in the proliferative capacity, a commonly used indicator of progenitors, among the rGMPs, cMoPs, and pre-monocytes.
rGMPs Sequentially Differentiate into cMoPs and PreMonocytes We next examined the developmental relationship among rGMPs, cMoPs, and pre-monocytes. Since rGMPs were able to differentiate into granulocytes and monocytes, we hypothesized that rGMPs differentiate into cMoPs by losing their granulocyte-differentiation potential and differentiate further into premonocytes. We sorted rGMPs with 100% purity and cultured the cells for 2 days under the FTS condition in vitro ( Figure 4A ). We found that the progenies from the rGMPs contained populations closely resembling cMoPs and pre-monocytes ( Figure 4B ), and those from cMoPs were similar to pre-monocytes (Figure 4C) . In this context, cMoPs never gave rise to rGMPs. These results strongly suggest that rGMPs sequentially differentiate into cMoPs and pre-monocytes.
Human cMoPs Have Monocyte-Committed Gene Expression Profiles
To examine whether cMoPs have a monocyte signature, meaning that they express suitable genes for monocyte differentiation, we performed multiple gene expression analyses of rGMPs, cMoPs, pre-monocytes, cMoP-derived CD14 + monocytes, and peripheral blood CD14 + monocytes. We included CMPs, which have a multi-myeloid cell differentiation potential and are not committed to monocyte differentiation, for comparison (Manz et al., 2002; Akashi et al., 2000) . As expected, the expression amounts of monocyte-specific genes were gradually increased during monocyte differentiation and, among the progenitors, the expression amounts of monocyte-specific genes (Hettinger et al., 2013) were lowest in CMPs, weak in rGMPs, and highest in cMoPs ( Figure 5A) . Notably, the expression amounts of SPI1 (PU.1), IRF8, CEBPB, and KLF4, which are critical transcriptional factors for monocyte development (Geissmann et al., 2010) , plateaued in the cMoPs, and those of CX3CR1 and CCR2, chemokine receptors that are necessary for monocyte migration (Stec et al., 2012) , were further increased at the pre-monocyte, cMoP-derived CD14 + monocyte, and peripheral blood CD14 + monocyte stages ( Figure 5A ). The hierarchical tree and plot flow of each population based on principle component (PC) 1 analysis fit with a sequential monocyte differentiation process and correlated well with our in vitro findings (Figures 5B and 5C) . In this context, we also calculated the Euclidean distances, which represent the distance of the differentiation stage between populations (Luc et al., 2012) . The distance from the cMoP-Mo or PB-Mo gradually decreased from the CMP to the pre-Mo (Figure 5D ). In addition, we used gene set enrichment analysis (GSEA) (Subramanian et al., 2005) to compare the expression amounts of a gene set that is known to be enriched in the CD14 + monocytes in human blood (a human-monocyte signature) (McGovern et al., 2014) among the cMoP-derived CD14 + monocytes, pre-monocytes, cMoPs, rGMPs, and CMPs. The human-monocyte signature increased with the degree of differentiation toward monocytes; i.e., cMoP-derived monocytes / pre-monocytes / cMoPs / rGMPs / CMPs ( Figure 5E ), confirming the level of monocyte commitment in each progenitor.
We further performed the hierarchical clustering analysis of rGMPs, cMoPs, and pre-monocytes (pre-Mo) ( Figures 6A and  6B) . We found 295 genes that were expressed in cMoPs at 2-fold higher or lower amounts than in preMo, and 260 genes that were expressed in cMoPs at 2-fold higher or lower amounts than in rGMPs. As expected, the expression pattern of the 519 genes that were expressed in cMoPs at 2-fold higher or lower amounts compared with rGMPs or preMo, switched around the amounts of cMoPs, and was clearly consistent with the sequential differentiation pathway, i.e., rGMPs/ cMoPs/ pre-Mo. Second, we extracted 36 genes that were commonly changed in both comparisons, i.e., in cMoPs versus rGMPs and in cMoPs versus preMo, and performed a hierarchical clustering analysis (Figures 6A and 6C) . The expression pattern of the 36 genes again fit the sequential differentiation pathway. Collectively, these data strongly supported the identification of cMoPs as monocyte-committed progenitors and the sequential differentiation from rGMPs to cMoPs to monocytes.
To assess the similarities between human and mouse cMoPs, we performed a cross-species analysis ( Figure S5 ). The tree clustering results showed similarity between human and mouse cMoPs ( Figures S5A and S5B ). We then extracted the genes that were expressed at statistically similar amounts between human and mouse cMoPs and categorized them based on GO terms. Notably, the human and mouse cMoPs commonly expressed gene sets that are characteristic of progenitors and not of mature cells ( Figures S5C and S5D) . In this analysis, the expression of the monocyte-specific genes ( Figure 5A ; Hettinger et al., 2013) and of 29 out of the 36 genes (Figures 6C) was correlated between human and mouse cMoPs ( Figures S5E-S5H ). These results suggest that the human and mouse cMoPs have common features, not only in terms of their monocyte differentiation potential but also in their gene expression profiles. Based on our findings and previous reports, we propose a revised myeloid cell developmental pathway, in which rGMPs develop into granulocytes and cMoPs, which give rise to all monocyte subsets via pre-monocytes ( Figure S6 ).
DISCUSSION
In this study, we subdivided human cGMPs based on their expression of FcgRI (CD64) and C-type lectin CLEC12A, and thus identified human cMoPs and rGMPs. The rGMPs gave rise to granulocytes and monocytes but did not differentiate into DCs or lymphocytes. Only the CD64 À fractions of the cGMP population had the potential to differentiate into DCs and lymphocytes. Finally, we showed the sequential differentiation from rGMPs into cMoPs into pre-monocytes; this finding was supported by multiple gene expression analyses using microarray data. To subdivide the human cGMP population and identify cMoPs, we screened a variety of cell-surface markers expressed on human monocytes, macrophages, and DCs, including C-type lectin-family members (CLEC9A, CLEC12A, DC-SIGN, etc.), cytokine receptors (CD115, CD116, etc.), chemokine receptors (CX 3 CR1, CXCR4, etc.), and others (CD64, etc.). Combined with the in vitro culture results of the subdivided populations, we identified CD64 and CLEC12A as useful markers for subdividing cGMPs and identifying a cMoP fraction within the cGMPs.
We compared differences and similarities between the characteristics of human and mouse cMoPs (Hettinger et al., 2013 that give rise solely to monocytes, and both express CD64, CLEC12A, and CD117. On the other hand, human cMoPs express CD135 but mouse cMoPs do not (Hettinger et al., 2013) . Mouse cMoPs are derived from MDPs (Hettinger et al., 2013) , while human cMoPs are derived from rGMPs-and partially via MDPs, because rGMPs had no DC potential. This difference might simply reflect differences in the myeloid cell developmental pathway between mice and humans. Alternatively, the mouse cGMP population might contain rGMPs. The existence of rGMPs that lack DC developmental potential is consistent with the separation of monocyte-derived DCs from cDCs and pDCs in the developmental process (Guilliams et al., 2014a) and implies that this separation occurs upstream of rGMP. In this context, we found that a fraction of the human MDPs overlapped with part of the rGMPs. The rGMPs did not give rise to DCs, while MDPs did, implying the possibility of heterogeneity in the MDP population. We recognize the limitations of the approach used in this study for determining the precise cellular composition of human rGMPs and their inter-relationships, which could be further refined using scRNA-seq. + monocytes in culture. Additional adoptive transfer experiments using optimized humanized mice or scRNA-seq analysis will strengthen the linear differentiation relationship, which remains for future studies.
Both human and mouse cGMPs give rise not only to granulocytes and monocytes, but also to DCs (Manz et al., 2002; Miller et al., 2012; Chicha et al., 2004; Shigematsu et al., 2004) . In addition to their myeloid differentiation potential, these progenitors also have a substantial lymphoid developmental potential (Doulatov et al., 2010; Ng et al., 2009 ). For instance, mouse cGMPs express high amounts of lymphoid genes and give rise to both T cells and B cells in vitro and in vivo (Ng et al., 2009 ). Human cGMPs, particularly from umbilical cord blood, also have the ability to differentiate into T cells (Doulatov et al., 2010) . Using Tst4-expressing Dll4 and Tst4 stromal cells combined with cytokine cocktails, an optimized method to evaluate progenitors' lymphoid potential (Ikawa et al., 2010) , we showed that the human rGMPs lacked lymphoid differentiation potential. In this context, the potential of rGMPs to differentiate into DCs was also impaired; the DC differentiation potential was confined to CD64 À cGMPs (R4 and R5). In addition to their monocyte and DC differentiation potentials, R4 and R5 gave rise to granulocyte and/or lymphocyte subsets. In this context, R5 generated a variety of colonies at the single-cell level, suggesting that R5 consists of multipotent progenitors, according to the current definition (Naik et al., 2013; Doulatov et al., 2010) . As R5 was multipotent, and human MLP-like cells lack megakaryocyteerythrocyte potential at the population level (Doulatov et al., 2010) , our data may fit a model in which the megakaryocyteerythrocyte lineages branch at the Lin À CD34 + CD38 À multipotent progenitor stage (Doulatov et al., 2010; Adolfsson et al., 2005; Sathe et al., 2014) . It will also be interesting to determine whether the counterpart of human rGMPs is present in conventional mouse GMPs.
Given that monocytes and monocyte-derived macrophages cause a variety of inflammatory disorders, including metabolic syndromes and tumor development, and cMoP efficiently can give rise to osteoclast (our unpublished data), our studies shed light not only on human monocyte differentiation, but also on possible therapeutic applications targeting cMoPs and monocytes.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Table S3 ). (C) Hierarchical clustering of the 36 genes that were commonly extracted by comparing cMoPs versus PreMo (295 genes) and cMoPs versus rGMPs (260 genes) described in (A). The numbers in the tree clustering indicate log 2 (each signal/mean). The data represent three independent experiments. Please also see Figure S5 . 
Cell-cycle Analysis
To assess the cell-cycle status of the progenitors, each progenitor was sorted and then fixed with 70% EtOH, pooled, and stocked at À80 C. The pooled progenitors were stained with DAPI.
Cell Culture and Analysis
For the myeloid-cell differentiation assay, 2 3 10 3 progenitor cells were cultured in 50 mL IMDM (Sigma) containing 10% FCS, 100 U/ml Penicillin/Streptomycin (Nacalai Tesque), and the following cytokine cocktails: 50 ng/ml hFlt3L (Miltenyi Biotech), 50 ng/ml hTPO (Kyowa Hakko Kirin), or 100 ng/ml hSCF (Miltenyi Biotech) (FTS condition), or cultured as reported previously . To induce monocyte-derived DCs, cells were cultured in medium supplemented with FTS plus 50 ng/ml GM-CSF (Miltenyi Biotech). To detect myeloid cells, progenies were stained with Abs against CD66b (G10F5; PerCP-Cy5.5), HLA-DR (L243; BV510), CD14 (M5E2; BV412), CD16 (3G1; PE-Cy5), CD123 (6H6; FITC), CD1c (L161; PE-Cy7), Streptavidin (APC-Cy7), CD26 (Biotin), Streptavidin (BV711) (all from Biolegend), BDCA-2 (AC144; Biotin or APC-Vio770), SIRP-alpha (Biotin) (all from Miltenyi Biotech), CD11c (B-ly6; APC) (BD), and CADM1 (9D2; Biotin) (MBL).
To assess the T cell and B-NK differentiation potentials, Tst4/Dll4 and Tst4 stromal cells were cultured with 100 mL RPMI-1640 medium (Sigma) containing 10% FCS, 100 U/ml Penicillin/Streptomycin (Nacalai Tesque), 1% Non-Essential Amino Acids (GIBCO), and 1% Sodium Pyruvate (GIBCO) (complete RPMI-1640 medium) in a 96-well plate. After 2 days, 10 cells from each progenitor were added to the stromal-cell culture plate and cultured for 4 weeks, with weekly changes of half the medium, which contained 5 ng/ml Flt3L and 5 ng/ml IL-7 (Miltenyi Biotech) to induce T cells, or 100 ng/ml SCF, 20 ng/mL IL-7, 50 ng/ml TPO, and 10 ng/ml IL-2 (Miltenyi Biotech) to induce B-NK cells (Doulatov et al., 2010; Kato et al., 2008) . In addition, after 2 weeks of culture, cells were passed through Nitex mesh with a 40-mm pore size (Nippon Rikagaku Kikai) and transferred onto fresh stromal cells in complete RPMI-1640 medium containing the appropriate cytokine cocktail. After 4 weeks of culture, the cells were collected and stained with Abs against hCD45 and CD3 to detect T cells, or hCD45, CD33, CD19, and CD56 to detect B-NK cells.
To assess proliferative capacity of cMoP and rGMP, 1 3 10 3 cells of each progenitor were sorted, labeled with CFSE (Life Technologies) and cultured with 2 mL of methylcellulose medium (MethoCult H4435-Enriched, StemCell Technologies, Inc.) for 7 days. The cells were analyzed on a FACSAria III or FACSCanto II (BD) in conjunction with FlowJo software (TreeStar).
Single-Cell Analysis
One hundred cMoPs or revised GMPs were cultured in 2 mL methylcellulose medium (MethoCult H4435-Enriched, StemCell Technologies, Inc.) supplemented with 10 ng/ml hTPO and 10 ng/ml Flt3L for 4.5 and 5.5 days using 6-well plate, respectively ( Figures 3A  and 3B ). cMoPs were cultured for 4.5 and 5.5 days using the same protocol ( Figures S4E and S4F ). Single colonies were picked up with a P20 pipette, suspended in 200 mL of PBS in each well of a round-bottom 96-well plate, and pipetted up and down in the well. The cell suspensions were spun down at 500 x g, and reacted with the Abs described in the ''Cell Culture and Analysis'' section for myeloid-cell detection. Cells were analyzed on a FACSAria III in conjunction with FlowJo software (TreeStar).
Data Acquisitions of Microarray
The PB-Mo, cMoP-Mo, preMo, cMoPs, rGMPs, and CMPs were sorted from at least 20 samples and pooled for one experiment. The cDNA from 6.622 ng total RNA was generated and amplified with the OvationÒ Pico WTA System V2 (NuGEN Technologies) according to the manufacturer's instructions. The amplified cDNA yield was checked with a NanoDrop ND-2000 Spectrophotometer (Thermo Scientific). Cyanine-3 (Cy3)-labeled cDNA was prepared from 2.0 mg cDNA using the SureTag Complete DNA Labeling Kit (Agilent) according to the manufacturer's instructions, followed by filtering with Amicon Ultra-0.5 mL Centrifugal Filters for DNA Purification and Concentration (Merck Millipore). Dye incorporation and cDNA yield were checked with a NanoDrop ND-2000 Spectrophotometer. Two micrograms of Cy3-labeled cDNA was brought up to 50 mL with 1x Agilent blocking agent and 1x Agilent hybridization buffer, and hybridized to SurePrint G3 Human GE 8x60K Microarray Ver2.0 (Agilent) for 17 hr at 65 C in a rotating Agilent hybridization oven. After hybridization, the microarrays were washed for 1 min at room temperature with GE Wash Buffer 1 (Agilent) and for 1 min with 37 C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation. The slides were scanned immediately after washing on the Agilent SureScan Microarray Scanner (G2600D) using the one-color scan setting for 8x60k array slides (scan area 61x21.6 mm, scan resolution 3 mm, dye channel set to green, and PMT set to 100%). The scanned images were analyzed with Feature Extraction Software 11.5.1.1 (Agilent) using default parameters to obtain background-subtracted and spatially detrended processed signal intensities. All procedures for extracting multiple expression data were performed by Takara Bio Inc.
Quantitative RT-PCR Total RNA was extracted from R4-or R5-derived CD141 hi DCs or from CD1c + DCs cultured as reported previously using the RNeasy Mini Kit (QIAGEN), and cDNA was synthesized with random hexamers and SuperScript III reverse transcriptase (Invitrogen). For real-time PCR, cDNA products equivalent to the RNAs from 333 cells were amplified with the LightCycler 480 SYBR Green I Master Mix (Roche Diagnostics). The data were normalized to the GAPDH mRNA level in each sample. The primers used for real-time PCR were as follows: TCF4 (E2-2) sense, 5 0 -GACAGATGTAAAAGGGTCCAAG-3 0 and antisense, 5 0 -CGTC TGCGATTCATAACTACTCA-3 0 ; IRF8 sense, 5 0 -AGAGCCCAGATTTTGAGGAAGTGA-3 0 and antisense, 5 0 -CAGTTGCCACGCC TAGTTTG-3 0 ; IRF4 sense, 5 0 -CTCATCACAGCTCACGTAGAAC-3 0 and antisense, 5 0 -CTGATGTGTTCTGGTAAATCGTAG-3 0 ; and GAPDH sense, 5 0 -GAAGTATGACAACAGCCTCAAG-3 0 and antisense, 5 0 -GTCCTTCCACGATACCAAAGT-3 0 . The primers were designed and synthesized by Nihon Gene Research Laboratories Inc.
Cytokine production by cMoP-derived monocytes CD14 + cMoP-derived monocytes were generated under the FTS condition and stimulated with/without LPS (20 ng/mL) and IFNg (20 ng/mL) (Miltenyi) for 24 hr in 50 mL of IMDM medium in a 384-well plate (10,000 cells/well). The culture supernatants were collected and analyzed by Legendplex (Biolegend).
Phagocytosis assay PB-or cMoP-derived CD14
+ monocytes were sorted and cultured with FITC-labeled Dextran (MW, 4000; Sigma) (final concentration; 1mg/mL) for 1 hr at 4 C or 37 C in IMDM medium. The cells were analyzed on a FACSAria III in conjunction with FlowJo software.
Allo-stimulation assay
In each well of a 96-well round-bottom plate, 5,000 PB DC subset cells were cultured simultaneously with 25,000 CFSE (Invitrogen)-labeled PB CD3 + CD4 + T cells and 25,000 PB CD3 + CD8 + T cells. The T cell proliferation was assessed by CSFE dilution on day 7 by FCM.
QUANTIFICATION AND STATISTICAL ANALYSIS
Microarray Analysis and Bioinformatics Raw data were analyzed using Subio Platform (ver. 1.18.4667, Subio Inc.). The gene set enrichment analyses (GSEA) were performed using GSEA (v.2.2.0 Broad Institute) (Subramanian et al., 2005) . The human blood monocyte signature was extracted from published microarray data (GSE35459) (McGovern et al., 2014) . Gene sets for cMoP-Mo, preMo, cMoPs, rGMPs, and CMPs were extracted from microarray data, as described above. In cluster analysis, we selected differentially expressed genes as probes (genes) with at least two-fold change of their log 2 -transformed mean intensities and p < 0.01 by Welch's two-tailed t test between cells. The cluster analyses were performed using Subio Platform software or pheatmap (R package) using Cluster and TreeView (de Hoon et al., 2004) , and statistical analyses were performed using R. To correct for bias between chips, we then performed quantile normalization (Bolstad et al., 2003) to all array data using R and Bioconductor (''limma'' package) (Ritchie et al., 2015) . The statistical tests of Venn diagram were performed by Fisher's exact test using R. Functional enrichment analysis was performed using Ingenuity Pathway Analysis (IPA). Spearman rank-correlation coefficients and Pearson product-moment correlation coefficient were calculated using R.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is Gene Expression Omnibus (GEO): GSE98090.
